Generic Cenestin Availability

Cenestin is a brand name of conjugated estrogens, approved by the FDA in the following formulation(s):

CENESTIN (estrogens, conjugated synthetic a - tablet;oral)

  • Manufacturer: TEVA BRANDED PHARM
    Approval date: March 24, 1999
    Strength(s): 0.625MG, 0.9MG
  • Manufacturer: TEVA BRANDED PHARM
    Approval date: March 13, 2000
    Strength(s): 1.25MG [RLD]
  • Manufacturer: TEVA BRANDED PHARM
    Approval date: June 21, 2002
    Strength(s): 0.3MG
  • Manufacturer: TEVA BRANDED PHARM
    Approval date: February 5, 2004
    Strength(s): 0.45MG

Has a generic version of Cenestin been approved?

No. There is currently no therapeutically equivalent version of Cenestin available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cenestin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical compositions of conjugated estrogens and methods for their use
    Patent 5,908,638
    Issued: June 1, 1999
    Inventor(s): Huber; Harold Eugene & Ryan; Mary Katherine
    Assignee(s): Duramed Pharmaceuticals, Inc.
    This invention relates to novel pharmaceutical compositions and methods for their preparation containing conjugated estrogens for the treatment of peri-menopausal, menopausal and post-menopausal disorders in women. The novel pharmaceutical compositions comprise a carrier base material and conjugated estrogens formed into a solid unit dosage form possessing a regular incremental release of the medicament upon oral administration. Further, the invention comprises the combination of conjugated estrogens with progestogens in a solid, shaped dosage unit. Specifically, the invention comprises the use of an organic excipient such as high molecular weight hydroxyalkyl alkylcelluloses. The use of an organic excipient such as hydroxypropylmethylcellulose in a stable, solid dosage formulation containing either conjugated estrogens alone or in combination with a progestogen is described.
    Patent expiration dates:
    • July 26, 2015
    • July 26, 2015
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)